Preprint
Short Note
Future Considerations for the mRNA–Lipid Nanoparticle Vaccine Platform
Altmetrics
Downloads
3447
Views
4311
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
17 December 2020
Posted:
21 December 2020
Read the latest preprint version here
Alerts
Abstract
Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new vaccine platform used by two of the leading vaccine candidates against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology.
Keywords:
Subject: Biology and Life Sciences - Biochemistry and Molecular Biology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated